China Resources Pharmaceutical extends sales deal with CR Healthcare

China Resources Pharmaceutical Group Limited announced a new Sales Framework Agreement 2026/2028 with CR Healthcare, effective from January 1, 2026, to December 31, 2028. This agreement replaces the existing framework, which expires on December 31, 2025. CR Healthcare is a wholly-owned subsidiary of CR Holdings, the company's controlling shareholder, making these continuing connected transactions subject to Chapter 14A of the Listing Rules.

Under the new agreement, the Group will continue to supply medical and pharmaceutical products, consumables, and medical devices to the Buyer Group (CR Healthcare and its associates, including Beijing Aerospace) and hospitals managed by them. The annual caps for sales of medical and pharmaceutical products and consumables are RMB1,850 million for 2026, RMB1,900 million for 2027, and RMB2,000 million for 2028. These caps represent an expected increase from historical sales.

Due to the highest applicable percentage ratios exceeding 5%, the agreement and its annual caps require reporting, announcement, annual review, and Independent Shareholders’ approval. An Extraordinary General Meeting will be convened for this purpose, where CR Holdings and its associates will abstain from voting.